The role of E255K/V-inclusive mutations in a Philadelphia-positive acute lymphoblastic leukemia with mutation evolution during sequential TKIs therapies

A case report

Miaomiao Zhao, MSa, Xiya Gui, BSb, Qiuling Wu, MDc, Linghui Xia, MDa, Yadan Wang, MDb,∗

Abstract

Rationale: Until recently, the survival rate in patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) was approximately 30%. Tyrosine kinase inhibitors (TKIs), which are a new class of drugs that target BCR-ABL fusion protein, have shown to be effective in treating Ph+ ALL in adults. However, the resistance mechanisms that promote the disease recurrence have altered the initial success of these revolutionary agents.

Patient concerns: A 71-year-old Chinese female patient who suffered from severe shoulder and back pain for 1 week.

Diagnosis: The patient was diagnosed with Ph+ ALL (B-cell) because of the following items. Complete blood count showed extremely abnormal white blood cell count (26.26 × 10⁹/l), hemoglobin concentration (65 g/l) and platelet count (14 × 10⁹/l). And because that Bone marrow aspirate showed 72.5% lymphoblasts and 59.30% lymphoblasts were confirmed by flow cytometry (FCM). At mean time, Real-time fluorescent quantitative PCR analysis confirmed that the P190 BCR/ABL fusion gene expression was 5.9%. Karyotype analysis indicated the following: 45, XX, −7, t (9; 22) (q34; q11) [cp3].

Interventions: The patient was treated with chemotherapy and different TKIs including imatinib, dasatinib, ponatinib, and bosutinib.

Outcomes: The patient achieved complete remissions with different TKIs after diagnose but relapsed afterward and died of infection.

Lessons: Multidrug-resistant mutations within the BCR-ABL1 kinase domain are an emerging clinical problem for patients receiving sequential TKIs therapy. Acquisition of E255KV-inclusive mutations is usually associated with ponatinib resistance, thus it is necessary to screen out new real pan-inhibitor compounds for all BCR/ABL mutations and figure out the potential efficacy of asciminib-based drug combinations in the future.

Abbreviations: CSF = cerebrospinal fluid, FCM = flow cytometry, MRD = the minimal residual disease, NGS = next-generation sequencing, Ph+ ALL = Philadelphia-positive acute lymphoblastic leukemia, TKIs = Tyrosine kinase inhibitors.

Keywords: BCR-ABL1 mutation, clonal evolution, compound mutation, E255K/V-inclusive mutation, Philadelphia chromosome-positive acute lymphoblastic leukemia, ponatinib
1. Introduction

Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) is a rare subtype of ALL characterized by enlarged spleen, liver and lymph nodes, paleness, fevers, bruising, bone pain, abnormal blood cell counts, and weight loss. Until recently, the survival rate in patients with Ph+ ALL was approximately 30%.[1] Yet, with the recent discovery of a new type of drugs, that is second- and third-generation Tyrosine kinase inhibitors (TKIs), which specifically target the Philadelphia chromosome, the survival rates have doubled. Recent clinical trials suggest that TKIs are more effective for elderly patients who cannot obtain a good outcome from intensive chemotherapy or allogeneic stem cell transplantation.[1] However, genetic instability fostering the acquisition of BCR-ABL1 kinase domain mutations is high, thus increasing the likelihood of subsequent TKI-resistant relapses.[2]

Prompt therapeutic reassessment and individualization based on mutation status are important to regain response and prevent disease progression.[1] It is important to differentiate compound mutations from polyclonal mutations in order to come up with the best treatment option. A risky element of sequential TKI treatment is the selection of BCR-ABL1 compound mutants, defined as harboring \( \geq 2 \) mutations in the same BCR-ABL1 allele that have the potential to confer resistance to multiple TKIs.[3]

Here we reported a single case of an elderly female patient with Ph+ ALL who achieved complete remissions with different TKIs after diagnose but relapsed afterward and died of recurrence, that is resistance to ponatinib and bosutinib caused by the burst of multiple mutations including E255K/V. We revealed the mutation evolution during sequential TKI therapies by monitoring BCR-ABL kinase domain mutations using next-generation sequencing (NGS). This study provided strong evidence that the mutation evolution of the BCR-ABL kinase domain can be a key factor influencing the treatment decision making in elderly Ph+ ALL patients. We also discovered that the E255K/V-inclusive mutations may be a dangerous indicator of resistance to ponatinib.

2. Case report

A 71-year-old Chinese female patient who suffered from severe shoulder and back pain for 1 week was admitted to our hospital on January 30, 2017. Complete blood count showed extremely abnormal white blood cell count (26.26 \( \times 10^9/\text{l} \)), hemoglobin concentration (65g/l) and platelet count (14 \( \times 10^9/\text{l} \)). Bone marrow aspirate showed 72.5% lymphoblasts (Fig. 1). Consequently, 59.30% lymphoblasts were confirmed by flow cytometry (FCM) (Fig. 1). Real-time fluorescent quantitative PCR analysis confirmed that the P190BCR/ABL fusion gene expression was 5.9% (Fig. 1). Karyotype analysis indicated the following: 45, XX, −7, t (9,22) (q34; q11) [cp3]. The patient had no history of other diseases, except moderate splenomegaly and hypertension. Moreover, the examination of cerebrospinal fluid (CSF) taken by lumbar puncture confirmed no involvement of the central nervous system. As a result, the patient was diagnosed with Ph+ ALL (B−cell).

On February 9, 2017, the patient was treated with conventional chemotherapy, that is DVP, which included daunorubicin (40mg/d) for the first 3 days, vindesine (4mg/d) on days 1, 8, 15, and 22, and prednisolone (1mg/kg/d for the first 14 days and 0.5mg/kg/d for the next 14 days), along with oral imatinib (400mg/d) treatment. At the same time, the patient received platelet transfusion, rehydration, and anti-infective treatment. Soon after the DVP treatment course, the patient’s abnormal clinical symptoms disappeared. Blood routine examination, bone marrow smear, and FCM testing showed that all indicators were within the normal range. Even though the expression of the BCR-ABL gene was still positive, with 18.3% (Fig. 1), this patient had obtained a complete hematological response. This patient was prescribed oral imatinib (400mg/d) for another 3 weeks. During the following month, the patient was treated with vindesine and prednisolone (vindesine 4mg/d on days 1, 8, 15, and 22, and prednisolone 1mg/kg/d for the first 14 days and 0.5mg/kg/d for the next 14 days) and oral imatinib (400mg/d) because of the severe pulmonary infection that appeared.
During the initial chemotherapy. After 4 months of imatinib therapy, bone marrow aspirate showed 2.5% lymphoblast the minimal residual disease (MRD) detection by FCM was 4.04%, and the level of the BCR-ABL gene expression decreased to 12.32% (Fig. 1). However, NGS showed Y253H (12.95%) point mutation (Fig. 2) in the BCR-ABL kinase domain, which indicated imatinib resistance.[4]

According to the protocol schedule, the patient was treated with DVP chemotherapy and oral dasatinib (100 mg/d) from June 5, 2017. One month later, bone marrow aspiration showed 1% lymphoblast, MRD was significantly reduced to 0.0026%, the level of BCR-ABL gene expression dropped to 0.28%, and no mutation was found in the BCR-ABL kinase domain (Fig. 1). The patient continued to take dasatinib orally without any other therapy for 3 months. No mutation in the BCR-ABL kinase domain was found in the first 2 months. However, during the last month of single oral dasatinib treatment (October 20, 2017), the patient experienced shoulder and back pain along with headaches. Bone marrow smear indicated 19% lymphoblast, MRD was 11.28%, and the expression of the BCR-ABL gene was 7.75% (Fig. 1). New point mutation F317I (32%) was found in the BCR-ABL kinase domain along with Y253H (58.44%) by NGS (Fig. 2). Meanwhile, lots of lymphoblasts found by CSF smear and FCM of CSF confirmed lymphoblast involvement of the central nervous system. The patient was then treated with dasatinib (100 mg/d) and chemotherapy consisting of methotrexate (1 g day 1), idarubicin (5 mg day 2), dexamethasone (5 mg day 1–day 5), temozolomide (200 mg day 3–day 7), along with lumbar puncture and intrathecal cytarabine (50 mg) and methotrexate (10 mg) injection twice a week. Although her CSF was clear without any lymphoblast, 2 weeks after chemotherapy, bone marrow smear indicated 62% lymphoblast and MRD was 32.43% (Fig. 1). The level of BCR-ABL transcript increased to 103.96%, and multiple point mutations were found in the BCR-ABL kinase domain including Y253H (48.25%), F317I (52.97%), T315I (3.03%), D276G (2.39%), and V289A (0.51%) (Fig. 2).

On December 17, 2017, the patient was treated with oral ponatinib (45 mg/d), which is the recommended treatment option for patients with the T315I mutation. During the first 2 months’ therapy of ponatinib, her blood routine examination had a significant improvement, and her pain symptoms were obviously alleviated at the beginning of therapy. The patient had another complete remission since lymphoblast, MRD, and the expression of the BCR-ABL gene decreased to normal level. Nevertheless, in March 2018, the patient relapsed, 6% lymphoblast were found in the bone marrow, MRD increased to 11.89%, the expression of BCR-ABL gene increased to 24.95% (Fig. 1). And various point mutations appeared in the BCR-ABL kinase domain including Y253H (56.26%), F317I (59.94%), E255K (31.65%), F359I (5.09%), and I418V (8.87%) (Fig. 2). After additional treatment with ponatinib (45 mg/d) for 20 days, bone marrow aspiration indicated increased lymphoblast. Furthermore, the karyotype analysis was as follows: 45, XX, −7, t (9, 22) (q34; q11) [9]/46, XX [11]. The patient was not eligible for enrollment in the clinical trial of cellular immunotherapy because of pulmonary infection.
Moreover, blinatumomab, an anti-CD19/CD3 bispecific antibody, is currently not available in China.

Consequently, the patient was treated with Bosutinib only (500 mg/d for 1 week) or in combination with standard chemotherapy (vincristine 2 mg per day Day 1, 8; prednim 60 mg per day Day 1–14); however, no improvements were observed. One month later [May 8, 2018] her bone marrow smear showed 76% lymphoblast, the MRD was up to 80.47%, the expression of BCR-ABL gene was 12.31% (Fig. 1) and more various point mutations appeared in the BCR-ABL kinase domain, including Y253H (90.49%), F317I (87.32%), E255K (73.5%), E255V (13.83%), F359I (23.08%), I418V (3.39%), and D276G (2.03%) (Fig. 2). Unfortunately, the patient suffered severe pulmonary infection again and died on progressing disease 1 month after. Her overall survival time was 1 year and 4 months.

In order to clarify the role of compound mutations for ponatinib and bosutinib resistance, we analyzed all the NGS data regarding the ABL domain mutation retrospectively. The NGS technology offers high sensitivity, but it cannot be used to discriminate between polyclonal and compound mutations. The average read length is between 200 to 300bp, which could not cover all the mutation sites on the ABL kinase domain, except site E255 and site Y253. The data of the last 2 detections after ponatinib resistance showed that all E255K or E255V mutations occurred on the Y253H mutation sequence reads. Finally, The Y253H/E255K (V) compound mutations were confirmed and the presence of other compound mutations was inferred by the detection of 2 mutations with a combined frequency >100% (e.g., 56.26% Y253H and 59.94% F317I) according to reference[5] (Table 1).

Next, by analyzing the crystal structure and discussing some literature results, we provided the structural explanation for the resistance of single point mutations (Y253H, E255K, and E255V) to second- and third-generation TKIs (Fig. 3 and see Fig. S1, http://links.lww.com/MD2/A108, supplemental content, which demonstrates the structure of point mutations to 4 TKIs.). The resistance of each mutation was assigned a value (RI, resistance index). We predicted the resistance of compound mutations using the sum of these indices and analyzing the resistance mechanism of compound mutation from the perspective of structure. The results showed that E255K single mutation and Y253H/E255K compound mutation conferred high- or intermediate-level resistance to 4 clinically available second- and third-generation TKIs (see Table S1, http://links.lww.com/MD2/A109, supplemental content, which illustrates the resistance indices of single and compound mutations to 4 TKIs). Besides, the E255V single mutation and Y253H/E255V compound mutation, which confers sensitivity to dasatinib, intermediate-level resistance to bosutinib, and high-level resistance to ponatinib, were most resistant to nilotinib.

Written informed consent was obtained from the patient's family for the publication of this case report.

3. Discussion

Here we report a single case of an elderly female patient with Ph+ ALL who was first treated with imatinib to dasatinib. The first complete hematological response was followed by rapid hematologic relapse, which was associated with Y253H (12.95%) and F317I (32%) point mutation, and some minor mutation T315I (3.03%), D276G (2.39%), and V289A (0.51%) point mutation. Next, the patient received ponatinib therapy; ponatinib is the only approved BCR-ABL tyrosine kinase inhibitor that is active against T315I mutation.[6] After the therapy, the patient was in complete remission, and no point mutation was found in the BCR-ABL kinase domain. Nevertheless, transient response to ponatinib was followed by the rapid third relapse with a novel major mutation E255K and a compound mutation Y253H/E255K. According to the recommendation of NCCN Guidelines of Acute Lymphoblastic Leukemia (Version 2, 2019), bosutinib is considered a good option for relapsed or refractory Ph+ ALL with E255V/K, F317LV/C/G, F359V/C/I, T315A, or Y253H mutations,[4] which matched the ABL mutation profile at the third relapse in our patient well. Finally, the patient was treated with bosutinib but unfortunately died due to severe pulmonary infection and progressing disease.

### Table 1

| Therapy course (month) | Therapy | Compound mutation | Frequency |
|-----------------------|---------|-------------------|-----------|
| 13                    | ponatinib | Y253H/E255K* | 31.65% |
| 15                    | bosutinib | Y253H/E255V* | 13.83% |
|                       |         | Y253H/F317I*    | U         |
|                       |         | Y253H/E255K*    | 7.35%    |
|                       |         | Y253H/F317I*    | U         |
|                       |         | Y253H/F359I     | U         |
|                       |         | F317V/F359I     | U         |

U = undetermined. Bold is in order to clarify the role of compound mutations for ponatinib and bosutinib resistance.

* Compound mutations, which were confirmed by NGS due to they are in the same amplified reads.

† Compound mutations, which were inferred by the detection of 2 mutations with a combined frequency >100%, according to reference[5].

### 3.1. The major possible reasons for ponatinib and bosutinib resistance in this patient

#### 3.1.1. Ponatinib could not overcome E255V/K mutation-based resistance.

A previous preclinical study indicated that the ponatinib ICS0 values for E255K/V (IC50 14/36) were higher than that of T315I (IC50 11).[6] The E255V mutation, which confers high-level resistance to imatinib and intermediate-level resistance to nilotinib and dasatinib, was most resistant to ponatinib.[7] Our computer structure analyses suggested that E255K and E255V shift the P-loop (Fig. 3), intruding on the ponatinib binding site, which results in drug-resistance. Furthermore, Cortes et al showed that Ph+ ALL patients with E255V/K at baseline achieved a worse response to ponatinib than chronic-phase chronic myeloid leukemia patients with the same mutation.[5] All the above data suggested that ponatinib, which is an active pan-inhibitor of BCR-ABL, including the T315I mutation, might not be effective for Ph+ ALL patients with E255V/K mutation-based resistance.

#### 3.1.2. Bosutinib may not be an optimal choice for relapsed or refractory Ph+ ALL with E255V/K mutations.

The previous studies have suggested that bosutinib monotherapy may not be effective for Ph+ ALL patients, especially those carrying more than 1 mutation (E255V, F317L, F359C).[8,9] This might be the reason why the FDA has not approved Bosutinib as the first-line treatment of the Ph+ ALL.[9] Moreover, Sara et al found that E255V/K mutation might be the reason for bosutinib-resistance.
because of high IC50 values. Our computer structure analyses show that E255K and E255V induce a conformational change of the P-loop and affect the binding of Bosutinib (Fig. 3). Accordingly, for patients with relapsed or refractory Ph+ ALL, especially those with E255K/V mutations, bosutinib may not be an optimal choice.

3.1.3. BCR-ABL1 compound mutants have increased the complexity of the mechanisms of resistance to TKIs. Several studies have suggested that the compound mutations are associated with the TKIs-resistance. For example, Zabriskie et al found that T315I-inclusive compound mutations significantly impair ponatinib binding and may lead to clinical resistance and relapse. In our patients, series BCR-ABL kinase domain mutations, that is Y253H/E255K and Y253H/E255V, that were confirmed by NGS, appeared during the end-stage. Our computational modeling results indicated that Y253H/E255K confers high- or intermediate-level resistance to all clinically available TKIs. Clinical data also further confirmed the resistance of the ponatinib to this compound mutation in BP-CML and Ph+ ALL patients. Compared to Y253H/E255K, in vitro experimental results and computational modeling have identified dasatinib as the only clinically available TKIs that retain potency against Y253H/E255V at clinically relevant levels. The superiority of dasatinib compared to ponatinib against the Y253H/E255V compound mutant was further confirmed by our computational modeling results, which revealed that the resistance index of ponatinib is higher than that of dasatinib (2 vs 0). Other possible compound mutations (Y253H/F317I, Y253H/F359I, and F317I/F359I) could also increase the complexity of the resistance
mechanisms to TKIs. It could be speculated that all these compound mutants are among the main mechanisms underlying ponatinib and bosutinib resistance.

Detection of compound mutations is more frequent among CML-BP and Ph+ ALL patients compared to those with CML-CP, thus suggesting an increased risk of compound mutation-based multidrug resistance in advanced disease. Immunotherapy, such as chimeric antigen receptor T-cells therapy, is considered a treatment option with the potential to overcome TKIs resistance based on ABL mutations. Unfortunately, the blinatumomab and inotuzumab ozogamicin are not available for Chinese patients because they have still not been approved by CFDA. Poor physical condition and multiple complications limited our patient from enrolling chimeric antigen receptor T-cells clinical trials. Finally, Y253H/E255K(V) and other possible compound mutations were fatal to the patient. Recently, limited our patient from enrolling chimeric antigen receptor T-cells therapy, is considered a treatment option with the potential to overcome TKIs resistance based on ABL mutations. Thus, asciminib-based drug combinations may offer a novel treatment option to overcome TKIs resistance in Ph+ ALL.

In conclusion, second and third-generation TKIs could be effective in patients with recurrent Ph+ ALL, while multidrug-resistant compound mutations within the BCR-ABL1 kinase domain are an emerging clinical problem for patients receiving sequential TKIs therapy. Therefore, it is of urgent importance to consider HSCT or novel immunotherapies and differentiate compound mutations from polyclonal mutations in order to come up with the best treatment option. Acquisition of E255K/V-inclusive mutations is usually associated with ponatinib resistance, thus it is necessary to screen out new real pan-inhibitor compounds for all BCR/ABL mutations and figure out the potential efficacy of asciminib-based drug combinations in the future.

(Supplementary material.doc, http://links.lww.com/MD2/A110).

Author contributions
Conceptualization: Miaomiao Zhao, Qiuling Wu, Linghui Xia.
Data curation: Miaomiao Zhao, Xiya Gui.
Project administration: Yadan Wang.
Writing – original draft: Miaomiao Zhao, Xiya Gui, Qiuling Wu.

Writing – review & editing: Miaomiao Zhao, Xiya Gui, Qiuling Wu, Linghui Xia, Yadan Wang.

References
[1] Soverini S, Bassan R, Lion T. Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges. J Hematol Oncol 2019;12:39.
[2] Ottmann O, Pfeifer H, Cayuela J-M, et al. Nilotinib (Tasigna®) and low intensity chemotherapy for first-line treatment of elderly patients with BCR-ABL1-positive acute lymphoblastic leukemia: final results of a prospective multicenter trial (EWALL-PH02). Blood 2018;132(Suppl 1):31.
[3] Shah NP, Skaggs BJ, Branford S, et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 2007;117:2562–9.
[4] Brown PA, Wieduwilt M, Logan A, et al. Guidelines insights: acute lymphoblastic leukemia, Version 1.2019. J Natl Compr Canc Netw 2019;17:414–23.
[5] Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013;369:1783–96.
[6] O’Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009;16:401–12.
[7] Redaelli S, Mologni L, Rostagno R, et al. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Am J Hematol 2012;87:E125–8.
[8] Khoury HJ, Cortes JE, Kantarjian HM, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 2012;119:3403–12.
[9] Gambacorti-Passerini C, Kantarjian HM, Kim DW, et al. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol 2015;90:755–68.
[10] Zabriskie MS, Eide CA, Tantravahi SK, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell 2014;26:428–42.
[11] Rafei H, Kantarjian HM, Jabbour EJ. Targeted therapy paves the way for the cure of acute lymphoblastic leukemia. Br J Haematol 2010;150:207–23.
[12] Wei G, Wang J, Huang H, et al. Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia. J Hematol Oncol 2017;10:150.
[13] Topp MS, Gokbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicenter, single-arm, phase 2 study. Lancet Oncol 2015;16:53–66.
[14] Eide CA, Zabriskie MS, Savage Stevens SL, et al. Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants. Cancer Cell 2019;36:431–43. e435.